Takeda’s Hat Trick Marks The First New Molecular Entity Of 2013
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda’s type 2 diabetes drug alogliptin – on its third pass through FDA – was cleared Jan. 25 as a single agent as Nesina, in combination with metformin as Kazano and in combination with pioglitazone as Oseni.